Today, high-risk early-stage HER2-positive breast cancer patients are most often recommended neoadjuvant treatment with a combination of monoclonal antibodies that bind to the extracellular domain of the HER2 receptor (e.g., trastuzumab and pertuzumab) together with chemotherapy [3, 11–13]. Here, ERBB2 is linked to breast cancer.